Iotrol, a new nonionic, water-soluble, hexiodinated dimeric contrast medium for
myelography, was used in clinical trials in 29 patients. The purpose of the study was to …

In order to examine the radiopacity, safety, and usefulness of iotrolan, a new dimeric,
nonionic, water-soluble contrast medium for myelography, a multicenter clinical study was …

As part of a clinical Phase III study of the nonionic, dimeric contrast medium iotrolan,
differences in opacification, tolerance, and effects on the electroencephalogram after …

In a prospective, randomized, double-blind study, 49 patients underwent lumbar
myelography using iotrol (24 patients) or metrizamide (25 patients). The diagnostic imaging …

Iotrolan is a new nonionic, dimeric contrast medium that is distinguished by its special
physicochemical and low chemotoxic properties. It displays near isotonicity with blood and …

In a double-blind study 238 patients were examined with lumbar myelography using iotrolan
or iohexol in randomized sequence in order to evaluate the image quality, the safety and …

The provisional results are presented of a comparative blind trial of iotrolan, iohexol and
iopamidol for lumbar myelography. The aim of the trial was to assess the relative safety …

Lumbar myelography was performed in 50 patients; 25 received iohexol (an investigational
aqueous contrast agent) and 25 received metrizamide. The two media produced …

Lumbar myelography was performed in 38 patients; 19 received iohexol (an investigational
aqueous contrast agent) and 19 received metrizamide. Iohexol is stable in solution, which is …

Iohexol and iopamidol, two new nonionic contrast media, have been extensively studied in
comparison with metrizamide for lumbar myelography. Review of the literature with statistical …